Personalis, Inc. - Common Stock (PSNL)
6.3700
-0.5500 (-7.95%)
NASDAQ · Last Trade: Jul 12th, 11:07 PM EDT
Jim Cramer advises against investing in Tempus AI due to its ongoing losses and suggests Pan American as a profitable alternative. Insmed is also considered speculative while the only viable option for autonomous vehicles is Tesla. Ouster's stock was downgraded and other companies experienced mixed price action.
Via Benzinga · July 10, 2025
Via Benzinga · July 9, 2025
Let's have a look at what is happening on the US markets after the closing bell on Wednesday. Below you can find the top gainers and losers in today's after hours session.
Via Chartmill · July 9, 2025

Via Benzinga · February 28, 2025

Via Benzinga · January 27, 2025
A revolution in oncology could help cancer survivors in the U.S. and bolster Guardant Health, Natera and Exact Sciences.
Via Investor's Business Daily · April 17, 2025
Via Benzinga · March 17, 2025

Ark Invest made significant trades on Friday, selling shares of RBLX, ROKU, PATH and buying shares of IBTA, PSNL, ABSI, and RXRX.
Via Benzinga · March 8, 2025

Via Benzinga · February 14, 2025

Via Benzinga · December 20, 2024

Via Benzinga · December 20, 2024

Shares of Merck & Co (MRK) continue to trend lower. If they reach the $95.00 level, there is a good chance they find support and reverse.
Via Benzinga · December 19, 2024

Via Benzinga · November 7, 2024

Via Benzinga · November 7, 2024

It deepened its involvement in a client and peer.
Via The Motley Fool · August 21, 2024

PSNL stock results show that Personalis beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024.
Via InvestorPlace · August 7, 2024